Research programme: MuSK agonist antibodies - Genentech

Drug Profile

Research programme: MuSK agonist antibodies - Genentech

Latest Information Update: 26 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genentech
  • Developer Genentech; NYU Langone Medical Center
  • Class Antibodies; Neuroprotectants
  • Mechanism of Action Receptor protein tyrosine kinase agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Amyotrophic lateral sclerosis; Myasthenia gravis

Most Recent Events

  • 20 Feb 2018 Preclinical trials in Amyotrophic lateral sclerosis in USA (Parenteral) before February 2018
  • 20 Feb 2018 Pharmacodynamics data from a preclinical trial in Amyotrophic lateral sclerosis released by Genentech and NYU Langone Health
  • 01 May 2015 Preclinical trials in Myasthenia gravis in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top